Humacyte Inc

For the period ended Sep 30, 2024. Filed Nov 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 8, 2024

HUMA$0.59+29.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands except for share and per share amounts)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2024	2023	2024	2023
Revenue	$—	$—	$—	$—
Operating expenses:
Research and development	22,926	18,552	67,943	56,370
General and administrative	7,307	6,070	18,367	17,495
Total operating expenses	30,233	24,622	86,310	73,865
Loss from operations	(30,233)	(24,622)	(86,310)	(73,865)
Other income (expense), net:
Interest income	911	1,369	3,252	4,323
Change in fair value of Contingent Earnout Liability	(8,489)	(1,144)	(38,653)	(11,708)
Interest expense	(2,438)	(1,463)	(6,769)	(4,872)
Change in fair value of derivatives	1,047	(135)	719	(234)
Employee retention credit	—	—	—	3,107
Loss on extinguishment of debt	—	—	—	(2,421)
Total other expense, net	(8,969)	(1,373)	(41,451)	(11,805)
Net loss and comprehensive loss	$(39,202)	$(25,995)	$(127,761)	$(85,670)
Net loss per share attributable to common stockholders, basic and diluted	$(0.33)	$(0.25)	$(1.10)	$(0.83)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted	119,408,565	103,444,246	115,623,616	103,357,087

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.